

Begoña Mellado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6758983/publications.pdf>

Version: 2024-02-01

42
papers

4,102
citations

331670
21
h-index

265206
42
g-index

44
all docs

44
docs citations

44
times ranked

5942
citing authors

#	ARTICLE	IF	CITATIONS
1	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2019, 381, 338-348.	27.0	885
2	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	13.7	778
3	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology, The, 2015, 16, 1473-1482.	10.7	762
4	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncology, The, 2011, 12, 1143-1150.	10.7	217
5	Interleukin 6, a Nuclear Factor- κ B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor- κ B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. Clinical Cancer Research, 2006, 12, 5578-5586.	7.0	147
6	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 1270-1284.	4.1	131
7	Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Molecular Cancer Therapeutics, 2006, 5, 665-675.	4.1	98
8	KIT Expression in Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2004, 28, 676-678.	3.7	95
9	Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 329-339.	4.1	92
10	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
11	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275.	7.1	75
12	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncology, The, 2022, 23, 248-258.	10.7	73
13	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 368-373.	1.9	64
14	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 709-713.	1.9	63
15	C-KIT EXPRESSION IN SARCOMATOID RENAL CELL CARCINOMA: POTENTIAL THERAPY WITH IMATINIB. Journal of Urology, 2004, 171, 2176-2180.	0.4	59
16	Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon. Journal of Clinical Oncology, 2002, 20, 4032-4039.	1.6	53
17	Nuclear factor- κ B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate, 2013, 73, 512-521.	2.3	52
18	Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clinical and Translational Oncology, 2009, 11, 5-10.	2.4	49

#	ARTICLE	IF	CITATIONS
19	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA); Tj ETQq1 1 0.784314 rgBT /Overlook 2017, 18, 672-681a.	10.7	49
20	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767.	5.9	31
21	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
22	Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 10604-10616.	1.8	21
23	Molecular biology of renal cell carcinoma. <i>Clinical and Translational Oncology</i> , 2006, 8, 706-710.	2.4	18
24	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 265-270.	1.9	18
25	Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon- γ in patients with metastatic melanoma. <i>Melanoma Research</i> , 2006, 16, 59-64.	1.2	17
26	Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 308-318.	4.4	17
27	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 127-136.	4.4	17
28	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	1.9	17
29	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	4.1	15
30	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 59165-59180.	1.8	15
31	The influence of treatment sequence in the prognostic value of <i>TMPRSS2-ERG</i> as biomarker of taxane resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 1970-1981.	5.1	13
32	Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 452-460.	1.9	11
33	Expression and mutational analyses of KIT and PDGFR α in sarcomatoid renal cell carcinoma. <i>Histopathology</i> , 2009, 55, 230-232.	2.9	9
34	Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. <i>BMC Cancer</i> , 2016, 16, 135.	2.6	7
35	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 594023.	2.8	7
36	Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial. <i>Clinical and Translational Oncology</i> , 2005, 7, 250-254.	2.4	5

#	ARTICLE	IF	CITATIONS
37	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	2.8	4
38	Radium-223 international early access program: results from the Spanish subset. <i>Future Oncology</i> , 2018, 14, 41-50.	2.4	3
39	Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 453-62.	0.2	3
40	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6235.	3.7	2
41	c-kit Overexpression in Chromophobe Renal Cell Carcinoma Is Not Associated With c-kit Mutation of Exons 9 and 11. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1544-1545.	3.7	1
42	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. <i>Medical Oncology</i> , 2019, 36, 29.	2.5	0